Baidu
map

Medscape:纤维肌痛非药物治疗可获良好效果

2015-01-23 超人也想当好医生 丁香园

JAMA杂志4月16日发表的一篇临床综述表示,目前人们对于纤维肌痛和其他“集中性”疼痛疾病已经有更深入的了解,并提出了有效的治疗方法。早在2012年10月4日在马萨诸塞州的哈佛医学院波士顿贝斯以色列女执事医疗中心大查房中召开的会议上已系统地总结了纤维肌痛的流行病学特点、病理学、诊断标准和治疗方法。 来自密歇根大学的Clauw教授在文章中写道,目前全球有高达2%到8%的人患有纤维肌痛,其临床主要症

JAMA杂志4月16日发表的一篇临床综述表示,目前人们对于纤维肌痛和其他“集中性”疼痛疾病已经有更深入的了解,并提出了有效的治疗方法。早在2012年10月4日在马萨诸塞州的哈佛医学院波士顿贝斯以色列女执事医疗中心大查房中召开的会议上已系统地总结了纤维肌痛的流行病学特点、病理学、诊断标准和治疗方法。

来自密歇根大学的Clauw教授在文章中写道,目前全球有高达2%到8%的人患有纤维肌痛,其临床主要症状全身大范围疼痛,并常伴有疲劳、记忆障碍、睡眠障碍。

该综述的证据来源于meta分析、同期循证治疗指南、和1955-2014年间纤维肌痛的相关医学文献。Clauw教授通过参考加拿大疼痛学会最新发布的指南,对纤维肌痛的治疗提出了建议,并根据相关证据将该治疗方案分为1-5级。

纤维肌痛最早的诊断依据发表于1990年:患者有慢性疼痛病史,并且其范围较广,查体可见多处肌肉压痛。然而相比之下,新的诊断依据主要基于患者的症状,且无需计数压痛部位。故新的调查表只需记录疼痛的部位、疲劳出现的时间和程度以及有无睡眠障碍、记忆障碍、头痛、肠易激和情绪障碍及其严重程度。

目前纤维肌痛已经可以在基层医疗机构得到正确的诊断及相应的治疗,只有在诊断不明确或治疗无效或合并有严重精神障碍的情况下才需转到专科诊治。

在现有的众多治疗纤维肌痛的方法中,非药物疗法能有效治疗纤维肌痛并得到的充分证据证明,其内容包括相关的健康知识教育、日常锻炼、认知行为治疗,而治疗药物则有三环类药物、血清去甲肾上腺素再摄取抑制剂、加巴喷丁。

对于配合的患者,最佳的治疗方案是联合药物治疗和非药物疗法。后者包括需要让患者了解到目前诊治所处困境及意识到通过减压、改善睡眠质量和适度锻炼来积极配合治疗的重要性。

医生需要根据患者疼痛等临床症状来指导用药。所有患者都应接受低剂量的环苯扎林、阿米替林或去甲阿米替林等三环类药物的完整疗程试验。血清去甲肾上腺素再摄取抑制剂则适用于伴有疲劳、精神低迷的患者,而伴有焦虑或睡眠障碍的患者则建议使用加巴喷丁。

有效的治疗方法或需联合应用多种药物。如非甾体类抗炎药和对乙酰氨基酚或有助于治疗伴有的由其他因素引起的外周疼痛,但应避免使用阿片类药物。

Clauw教授在文章中写道,目前人们对于纤维肌痛和其他“集中性”疼痛的了解更深入了,认为它可能只是一个不完整的诊断(discrete diagnosis)或作为严重的中枢神经系统疼痛的一系列症状中的一个特征,并且常伴有乏力、记忆障碍、睡眠障碍和情绪障碍。并且目前纤维肌痛或可获得有效的治疗。

Clauw教授目前在辉瑞等机构担任顾问,并作为其科学顾问委员会的成员,且能从这些机构得到研究资助。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1725735, encodeId=88571e25735b7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Jul 30 18:31:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897971, encodeId=9e6b189e9715a, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jan 28 23:31:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350969, encodeId=484513509692c, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 25 05:31:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458569, encodeId=6e6914585690b, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Jan 25 05:31:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606385, encodeId=59dd160638501, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 25 05:31:00 CST 2015, time=2015-01-25, status=1, ipAttribution=)]
    2015-07-30 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1725735, encodeId=88571e25735b7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Jul 30 18:31:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897971, encodeId=9e6b189e9715a, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jan 28 23:31:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350969, encodeId=484513509692c, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 25 05:31:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458569, encodeId=6e6914585690b, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Jan 25 05:31:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606385, encodeId=59dd160638501, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 25 05:31:00 CST 2015, time=2015-01-25, status=1, ipAttribution=)]
    2015-01-28 smlt2008
  3. [GetPortalCommentsPageByObjectIdResponse(id=1725735, encodeId=88571e25735b7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Jul 30 18:31:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897971, encodeId=9e6b189e9715a, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jan 28 23:31:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350969, encodeId=484513509692c, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 25 05:31:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458569, encodeId=6e6914585690b, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Jan 25 05:31:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606385, encodeId=59dd160638501, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 25 05:31:00 CST 2015, time=2015-01-25, status=1, ipAttribution=)]
    2015-01-25 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1725735, encodeId=88571e25735b7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Jul 30 18:31:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897971, encodeId=9e6b189e9715a, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jan 28 23:31:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350969, encodeId=484513509692c, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 25 05:31:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458569, encodeId=6e6914585690b, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Jan 25 05:31:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606385, encodeId=59dd160638501, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 25 05:31:00 CST 2015, time=2015-01-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1725735, encodeId=88571e25735b7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Jul 30 18:31:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897971, encodeId=9e6b189e9715a, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jan 28 23:31:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350969, encodeId=484513509692c, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 25 05:31:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458569, encodeId=6e6914585690b, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Jan 25 05:31:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606385, encodeId=59dd160638501, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 25 05:31:00 CST 2015, time=2015-01-25, status=1, ipAttribution=)]

相关资讯

Circulation:服用6个月阿托伐他汀不减弱肌肉强度

      尽管医生经常声称,他汀类药引起肌痛,但在STOMP试验之前,临床试验并没有仔细观察过这些药物对肌肉功能的效应。STOMP试验由Beth Parker 博士(哈特福德医院)牵头,结果显示,6个月大剂量阿托伐他汀不削弱患者的肌肉强度,但确实会提高患者肌酸激酶水平,导致肌痛。该试验结果发表在2012年11月26日的在线《循环》杂志上[Circulation 20

Baidu
map
Baidu
map
Baidu
map